J. Safra Sarasin Holding AG Sells 5,380 Shares of HCA Healthcare, Inc. $HCA

J. Safra Sarasin Holding AG lowered its position in shares of HCA Healthcare, Inc. (NYSE:HCA) by 46.6% during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 6,153 shares of the company’s stock after selling 5,380 shares during the period. J. Safra Sarasin Holding AG’s holdings in HCA Healthcare were worth $2,357,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of HCA Healthcare by 11.9% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 25,454 shares of the company’s stock valued at $8,796,000 after buying an additional 2,698 shares during the last quarter. Park Place Capital Corp increased its position in HCA Healthcare by 2,336.0% during the 2nd quarter. Park Place Capital Corp now owns 1,218 shares of the company’s stock valued at $474,000 after purchasing an additional 1,168 shares during the period. Harrell Investment Partners LLC boosted its stake in shares of HCA Healthcare by 176.3% in the 2nd quarter. Harrell Investment Partners LLC now owns 1,815 shares of the company’s stock valued at $695,000 after purchasing an additional 1,158 shares during the last quarter. Brown Advisory Inc. boosted its position in HCA Healthcare by 53.9% during the first quarter. Brown Advisory Inc. now owns 4,630 shares of the company’s stock valued at $1,600,000 after acquiring an additional 1,622 shares during the last quarter. Finally, Farther Finance Advisors LLC boosted its position in shares of HCA Healthcare by 26.9% during the 1st quarter. Farther Finance Advisors LLC now owns 1,141 shares of the company’s stock valued at $395,000 after purchasing an additional 242 shares in the last quarter. 62.73% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

HCA has been the topic of a number of research analyst reports. JPMorgan Chase & Co. increased their price target on HCA Healthcare from $360.00 to $370.00 and gave the stock a “neutral” rating in a report on Monday, August 4th. Wells Fargo & Company decreased their price target on shares of HCA Healthcare from $385.00 to $375.00 and set an “equal weight” rating for the company in a research note on Thursday, August 14th. Morgan Stanley reduced their target price on HCA Healthcare from $410.00 to $400.00 and set an “equal weight” rating for the company in a research note on Monday, July 28th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $444.00 price target on shares of HCA Healthcare in a report on Tuesday, August 26th. Finally, Robert W. Baird raised their price objective on shares of HCA Healthcare from $380.00 to $423.00 and gave the company a “neutral” rating in a research note on Thursday, August 14th. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and nine have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $407.75.

Insiders Place Their Bets

In other news, EVP Michael S. Cuffe sold 3,836 shares of HCA Healthcare stock in a transaction dated Monday, September 8th. The shares were sold at an average price of $418.84, for a total value of $1,606,670.24. Following the completion of the transaction, the executive vice president owned 31,503 shares in the company, valued at $13,194,716.52. This trade represents a 10.85% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 1.30% of the stock is owned by corporate insiders.

HCA Healthcare Stock Performance

Shares of NYSE:HCA opened at $429.52 on Friday. The company has a market capitalization of $100.50 billion, a P/E ratio of 18.05, a price-to-earnings-growth ratio of 1.34 and a beta of 1.40. HCA Healthcare, Inc. has a fifty-two week low of $289.98 and a fifty-two week high of $432.36. The company’s 50-day moving average is $397.53 and its 200 day moving average is $372.39.

HCA Healthcare (NYSE:HCA) last released its earnings results on Friday, July 25th. The company reported $6.84 earnings per share for the quarter, beating analysts’ consensus estimates of $6.20 by $0.64. The firm had revenue of $18.61 billion during the quarter, compared to the consensus estimate of $18.49 billion. HCA Healthcare had a net margin of 8.21% and a negative return on equity of 7,363.11%. The company’s revenue was up 6.4% compared to the same quarter last year. During the same period in the prior year, the firm earned $5.50 EPS. HCA Healthcare has set its FY 2025 guidance at 25.500-27.000 EPS. As a group, research analysts predict that HCA Healthcare, Inc. will post 24.98 earnings per share for the current year.

HCA Healthcare Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, September 30th. Investors of record on Tuesday, September 16th were paid a $0.72 dividend. This represents a $2.88 dividend on an annualized basis and a yield of 0.7%. The ex-dividend date was Tuesday, September 16th. HCA Healthcare’s payout ratio is currently 12.11%.

About HCA Healthcare

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.